Current biological therapies for inflammatory bowel disease.
about
Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycleTacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.Autoregulation of Th1-mediated inflammation by twist1.Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.
P2860
Current biological therapies for inflammatory bowel disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Current biological therapies for inflammatory bowel disease.
@ast
Current biological therapies for inflammatory bowel disease.
@en
type
label
Current biological therapies for inflammatory bowel disease.
@ast
Current biological therapies for inflammatory bowel disease.
@en
prefLabel
Current biological therapies for inflammatory bowel disease.
@ast
Current biological therapies for inflammatory bowel disease.
@en
P356
P1476
Current biological therapies for inflammatory bowel disease.
@en
P2093
Axel U Dignass
Daniel C Baumgart
P304
P356
10.2174/1381612043382413
P577
2004-01-01T00:00:00Z